Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Model‐informed drug development (MIDD) was central to the development of the oral proteasome inhibitor ixazomib, facilitating internal decisions (switch from body surface area (BSA)‐based to fixed dosing, inclusive phase III trials, portfolio prioritization of ixazomib‐based combinations, phase III...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Pharmacol Ther
Hlavní autoři: Gupta, Neeraj, Hanley, Michael J., Diderichsen, Paul M., Yang, Huyuan, Ke, Alice, Teng, Zhaoyang, Labotka, Richard, Berg, Deborah, Patel, Chirag, Liu, Guohui, van de Velde, Helgi, Venkatakrishnan, Karthik
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Reviews
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6585617/
https://ncbi.nlm.nih.gov/pubmed/29446068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1047
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky